Hepatitis C is a chronic liver disease that is transmitted primarily through blood. Hepatitis C has not yet developed a vaccine to prevent it, and its onset and course are insidious. Many patients do not pay enough attention to it and do not receive timely treatment, and it gradually develops into cirrhosis and liver cancer. For hepatitis C, the standard regimen used in China is interferon combined with ribavirin. This regimen can cure many patients, but there are large side effects, contraindications, high relapse rate in some patients, and intolerance of side effects. Since 2014, breakthroughs have been made in the treatment of hepatitis C. Some effective drugs for hepatitis C have been marketed abroad, such as Sofosbuvir, Ledipavir, Daclatasvir, Gilead II Harvoni, etc. For patients with different genotypes and different treatment regimens, these new hepatitis C drugs can cure hepatitis C with a cure rate of more than 90% and very few side effects. Although these drugs have been marketed in Europe and the United States and other countries, they have not yet been marketed in China. It usually takes some time for new foreign drugs to hit the market in China, usually 3-5 years. Patients with urgent needs are advised to seek medical treatment in a timely manner.